PUBLISHER: The Business Research Company | PRODUCT CODE: 1415651
PUBLISHER: The Business Research Company | PRODUCT CODE: 1415651
“Epidural Abscess Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on epidural abscess treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for epidural abscess treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The epidural abscess treatment market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
Epidural abscess treatment refers to the treatment of a rare disorder that is characterized by an infection in the area between the bones of the skull or spine and the membranes covering the brain and spinal cord. Epidural abscess treatment is used to manage symptoms, slow down the progression of the disease and prevent complications.
The main types of epidural abscesses are intracranial and intraspinal. An intracranial epidural abscess refers to an infection between the skull's bones and the membranes encasing the brain and spinal cord. These can be treated by various treatments, including antifungals, antibiotics and surgery, which are used by various end-users, such as hospitals, pharmacies, specialty clinics and others.
The epidural abscess treatment market research report is one of a series of new reports from The Business Research Company that provides epidural abscess treatment market statistics, including epidural abscess treatment industry global market size, regional shares, competitors with an epidural abscess treatment market share, detailed epidural abscess treatment market segments, market trends and opportunities and any further data you may need to thrive in the epidural abscess treatment industry. This epidural abscess treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The epidural abscess treatment market size has grown strongly in recent years. It will grow from $38.33 billion in 2023 to $41.11 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of epidural abscesses, high healthcare expenditure, increasing awareness of the disease, growing demand for combination therapies.
The epidural abscess treatment market size is expected to see strong growth in the next few years. It will grow to $52.89 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growing geriatric population, government initiatives, investment in epidural abscess research and development, growing incidence of spinal epidural abscesses. Major trends in the forecast period include innovations in healthcare technology, digital health technologies in epidural abscess care, artificial intelligence (ai) in epidural abscess diagnosis and treatment, affordable epidural abscess treatments.
The growth of the epidural abscess treatment market is expected to be driven by the rising prevalence of neurological disorders. Neurological disorders encompass medical conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. Common examples of neurological disorders include acute spinal cord injury, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), among others. Epidural abscess treatment is a crucial approach for managing these neurological disorders. It typically involves timely surgical drainage of the abscess and antibiotic therapy, which helps prevent compression of the spinal cord and nerves, relieving pressure. For instance, as of March 2022, the Alzheimer's Association, a nonprofit organization in the United States, reported that approximately 6.7 million Americans aged 65 and older are living with Alzheimer's in 2023. This number is projected to increase to 12.7 million by 2050. Consequently, the growing prevalence of neurological disorders is serving as a driving factor for the expansion of the epidural abscess treatment market.
The increasing prevalence of intravenous drug use is expected to be a driving force in the growth of the epidural abscess treatment market in the future. Intravenous drug use, which involves the direct injection of substances into the bloodstream using hypodermic needles and syringes, can result in epidural abscess when contaminated injection equipment or drugs introduce harmful bacteria or pathogens into the bloodstream. This heightened risk of epidural abscess due to intravenous drug use has created a demand for specialized care, treatments, and preventive measures. For instance, as reported by the United Nations Office on Drugs and Crime in June 2023, there was a global estimate of 13.2 million people engaged in injecting drugs in 2021, signifying an 18% increase from the 11.2 million reported in 2020. Hence, the growing incidence of intravenous drug use is poised to be a significant driver of the epidural abscess treatment market's expansion.
Major players in the epidural abscess treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma, Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, UCB Pharma, Sun Pharmaceutical Industries Limited, Kyowa Hakko Kirin Co. Ltd., Ferring B.V., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Limited, Alembic Limited, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals .
The elevated expenses linked to the treatment of epidural abscesses may significantly impede the growth of the epidural abscess treatment market. The costs associated with treating epidural abscesses can be substantial and can vary based on multiple factors, including surgical interventions, antibiotic therapy, the duration of hospitalization, and individual patient considerations. For instance, data from September 2021, published by Elsevier Inc., a Netherlands-based academic publishing company, highlights that treating epidural abscesses can be costly, especially if patients require an extended hospital stay, contributing to increased treatment expenses. Hence, the high treatment costs associated with epidural abscesses can present a hindrance to the expansion of the epidural abscess treatment market.
In March 2022, AbbVie Inc., a pharmaceutical company based in the United States, completed the acquisition of Syndesi Therapeutics SA for an approximate sum of $1 billion. This strategic acquisition is poised to facilitate AbbVie Inc.'s expansion within the field of neuroscience by incorporating novel synapse vesicle protein 2A modulators into its portfolio. Syndesi Therapeutics SA, headquartered in Belgium, is a biotechnology company with a focus on the development of therapies for spinal disorders, including conditions such as epidural abscesses.
Rise In Healthcare Expenditures
North America was the largest region in the epidural abscess treatment market in 2023. The regions covered in epidural abscess treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the epidural abscess treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epidural abscess treatment market consists of revenues earned by entities by providing surgical intervention, myelography, magnetic resonance imaging (MRI) and computed tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidural abscess treatment market also includes sales of vancomycin, gentamicin and ceftriaxone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.